We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,953.00
Bid: 6,953.00
Ask: 6,955.00
Change: -57.00 (-0.81%)
Spread: 2.00 (0.03%)
Open: 7,001.00
High: 7,172.00
Low: 6,943.00
Yest. Close: 7,010.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Hedge funds bleed as AbbVie reconsiders Shire bid

* Hedge funds' hit as Shire slumps * AbbVie reconsiders its bid * John Paulson and Paul Singer have stakes in Shire By Sudip Kar-Gupta and Nishant Kumar LONDON, Oct 15 (Reuters) - Some of the world's best known hedge funds lost hundreds of millions of dollars in the value

15 Oct 14 15:51

BUZZ-Shire Plc: Back to where it all started as M&A premium vanishes

(Updated) ** Shire shares slammed after AbbVie says it is reconsidering inversion deal ** Sharpest one-day drop for Shire shares since February 2002, wipes off $14 billion in its market value and takes stock back where it was when news of AbbVie deal first broke in June ** Even

15 Oct 14 12:14

UPDATE 3-AbbVie cools on $55 bln Shire deal after U.S. tax changes

* AbbVie says it is reconsidering backing for deal * Shire shares down 27 percent * AbbVie board to meet on Oct. 20 * Deal was partly motivated by tax benefits * Shire urges AbbVie to stick to original plan (Adds further details) By Paul Sandle and Sarah Young <

15 Oct 14 11:48

UK WINNERS & LOSERS: Takeover News Sinks Shire But Drives CSR Higher

15 Oct 14 10:54

2nd UPDATE: Shire Urges AbbVie To Proceed With Takeover, Notes Big Break Fee

15 Oct 14 09:30

UPDATE 2-AbbVie cools on $55 bln Shire deal after U.S. tax changes

* AbbVie says reconsidering backing for deal * Shire shares down 27 percent * AbbVie board to meet on Oct. 20 * Deal was partly motivated by tax benefits * Shire urges AbbVie to stick to original plan (Adds background, reaction) By Paul Sandle and Sarah Young <p

15 Oct 14 08:15

BUZZ-Shire: back to where it all started as M&A premium vanishes

** Shire shares slammed after AbbVie says it is reconsidering deal. ** Sharpest one-day drop for Shire shares since Feb 2002 wipes off $14 bln in its market value and takes stock right back where it was when news of AbbVie deal first broke in June. ** Even after drop Shire is second-b

15 Oct 14 07:27

AbbVie To Reconsider Shareholder Recommendation On Inversion Deal For Shire

15 Oct 14 05:32

UPDATE 2-Ex-Merck analyst faces insider trading charges on merger tips

(Adds comment from Merck spokeswoman in paragraph eight, updates court appearance status in paragraph six) By Emily Flitter NEW YORK, Oct 14 (Reuters) - Federal prosecutors in New York charged a former Merck & Co Inc employee with conspiracy to commit fraud for tipping a contact about

14 Oct 14 20:52

UPDATE 1-Ex-Merck analyst faces insider trading charges on merger tips

(Adds details from complaint) By Emily Flitter NEW YORK, Oct 14 (Reuters) - Federal criminal prosecutors in New York charged a former Merck & Co Inc employee with conspiracy to commit fraud for tipping a contact about potential mergers, including Merck's takeover of Idenix Pharmaceuti

14 Oct 14 15:46

AstraZeneca looks to EU decision for next cancer drug boost

* EU agency to decide on olaparib in ovarian cancer next week * AstraZeneca sees drug as potential $2 bln-a-year seller * Expectations rising for company's cancer drug pipeline By Ben Hirschler LONDON, Oct 14 (Reuters) - AstraZeneca's cancer drug pipeline, already on a rol

14 Oct 14 13:02

UK BROKER RATINGS: HSBC Upgrades IAG To Overweight From Neutral

14 Oct 14 08:37

UK MORNING BRIEFING: Burberry And Hargreaves Lansdown Lead Declines

14 Oct 14 07:32

BUZZ-AstraZeneca: broker boost

** Drugmaker AstraZeneca trades around one-week highs on the back of BofA Merrill Lynch upgrade to "buy", from "neutral". ** Stock up 0.6 pct, sixth-top riser on Britain's FTSE 100 , which sheds 0.4 pct. ** BofA ML highlights dramatic pipeline progression, driven by a change in R&D pr

14 Oct 14 07:32

Monday broker round-up UPDATE

Amino Technologies: Northland Capital upgrades to buy with a target price of 100p. Anglo American: Canaccord Genuity initiates with a target price of 1720p and a buy recommendation. Credit Suisse upgrades to outperform with a target price of 1800p. Associated British Foods: Societe Generale upgrade

13 Oct 14 09:32

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.